LPS-binding protein mediates LPS-induced liver injury and mortality in the setting of biliary obstruction.
It is generally accepted that low levels of lipopolysaccharide (LPS)-binding protein (LBP) augment the cell's response to LPS, whereas high levels of LBP have been shown to inhibit cell responses to LPS. Clinical studies and in vitro work by our group have demonstrated that, in the setting of liver disease, increased or acute-phase levels of LBP may actually potentiate rather than inhibit an overwhelming proinflammatory response. Therefore, in the present studies we sought to determine the role of acute-phase LBP in mediating morbidity and mortality in animals challenged with LPS in the setting of biliary obstruction. Using LBP-deficient mice and LBP blockade in wild-type mice, we demonstrate that high levels of LBP are deleterious in the setting of cholestasis. Following biliary obstruction and intraperitoneal LPS challenge, hepatic injury, hepatic neutrophil infiltration, and mortality were significantly increased in animals with an intact LBP acute-phase response. Kupffer cell responses from these animals demonstrated a significant increase in several inflammatory mediators, and Kupffer cell-associated LBP appears to be responsible for these differences, at least in part. Our results indicate that the role of LBP signaling in inflammatory conditions is complex and heterogeneous, and elevated levels of LBP are not always protective. Increased LBP production in the setting of cholestatic liver disease appears to be deleterious and may represent a potential therapeutic target for preventing overwhelming inflammatory responses to LPS in this setting.
Minter
Rebecca M
RM
Univ. of Michigan, Dept. of Surgery, 1500 E. Medical Center Dr., SPC 5343, Taubman Center TC2210D, Ann Arbor, MI 48109-5343, USA. rminter@umich.edu
Bi
Xiaoming
X
Ben-Josef
Gal
G
Wang
Tianyi
T
Hu
Bin
B
Arbabi
Saman
S
Hemmila
Mark R
MR
Wang
Stewart C
SC
Remick
Daniel G
DG
Su
Grace L
GL
D000209:Acute-Phase Proteins / Q000172:deficiency / Q000235:genetics / Q000378:metabolism*; D000818:Animals; D002352:Carrier Proteins / Q000235:genetics / Q000378:metabolism*; D001651:Cholestasis, Extrahepatic / Q000150:complications / Q000276:immunology* / Q000473:pathology; D003135:Common Bile Duct / Q000601:surgery; D004195:Disease Models, Animal; D019446:Endotoxemia / Q000150:complications / Q000276:immunology* / Q000473:pathology; D005260:Female; D018836:Inflammation Mediators / Q000378:metabolism; D007728:Kupffer Cells / Q000276:immunology / Q000378:metabolism; D008026:Ligation; D008070:Lipopolysaccharides; D008099:Liver / Q000276:immunology* / Q000473:pathology; D008107:Liver Diseases / Q000276:immunology* / Q000473:pathology; D008562:Membrane Glycoproteins / Q000172:deficiency / Q000235:genetics / Q000378:metabolism*; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D020556:Neutrophil Infiltration; D013997:Time Factors; D000099231:Lipopolysaccharide-Binding Protein
D000209:Acute-Phase Proteins; D002352:Carrier Proteins; D018836:Inflammation Mediators; D008070:Lipopolysaccharides; D008562:Membrane Glycoproteins; D000099231:Lipopolysaccharide-Binding Protein